Skeletal muscle dysfunction in critical care: wasting, weakness, and rehabilitation strategies

Zudin Puthucheary1, Stephen Harridge, Nicholas Hart

  • 1Lane Fox Respiratory Unit, Guy's and St Thomas' Foundation Trust and Kings College, London, UK.

Critical Care Medicine
|December 18, 2010
PubMed

Insights

Critical illness causes skeletal muscle wasting and functional impairment. Understanding these effects and mechanisms can guide new treatments to prevent muscle loss in intensive care patients.

Area of Science:

  • Critical care medicine
  • Muscle physiology
  • Pathophysiology

Background:

  • Skeletal muscle wasting is a common complication in critically ill patients.
  • This muscle loss leads to significant functional impairment and prolonged recovery.
  • The underlying mechanisms of muscle wasting during critical illness are not fully understood.

Purpose of the Study:

  • To investigate the trajectory of skeletal muscle loss in critical illness.
  • To evaluate the relationship between muscle wasting and functional impairment.
  • To elucidate the mechanisms of muscle wasting in early and recovery stages of critical illness.

Main Methods:

  • Focused examination of muscle morphology.
  • Analysis of muscle protein turnover.
  • Investigation of associated muscle-signaling pathways.

Main Results:

  • Critical illness significantly impacts muscle morphology and protein dynamics.
  • Specific signaling pathways are implicated in muscle wasting during critical illness.
  • Early and recovery stages exhibit distinct changes in muscle characteristics.

Conclusions:

  • Understanding muscle wasting mechanisms is crucial for developing targeted therapies.
  • Novel pharmacologic and nonpharmacologic strategies can potentially prevent or treat muscle wasting.
  • Interventions aimed at muscle morphology, protein turnover, and signaling pathways are promising.

Related Concept Videos

Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Muscle Recovery and Fatigue01:24

Muscle Recovery and Fatigue

Muscle fatigue refers to the decline in a muscle's ability to maintain the force of contraction after prolonged activity. It primarily stems from changes within muscle fibers. Even before experiencing muscle fatigue, one may feel tired and have the urge to stop the activity. This response, known as central fatigue, occurs due to changes in the central nervous system, namely the brain and spinal cord. While there is no single mechanism that induces fatigue, it may serve as a protective response...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...